Objective: Osteopontin (OPN), a phosphorylated sialoprotein, has been shown to overexpress
in a variety of cancers and to contribute tumor progression and metastasis by increasing cell
migration and adhesion. In the current study, we aimed to investigate the prognostic and predictive
role of OPN in patients with advanced gastric cancer.
Methods: A total of 42 consecutive chemonaive patients with advanced gastric cancer and 29
healthy controls were included. The patients were treated with a modified DCF regimen. The blood
samples were obtained before each chemotherapy cycle from the patients and once from the
healthy controls. The plasma OPN is measured by ELISA.
Results: The overall response and disease stabilization rates were 25% and 72%, respectively. The
median serum OPN level of the patient group was significantly higher compared to healthy controls
(176.9 ng/ml (range: 41.5 -521.4) vs 64.3 ng/ml (range 42.1-105.3 ng/ml), p<0.0001). The median
overall survival time was 7.0 ± 1.1 (95% CI: 4.9–9.2) months and 1-year overall survival rate
was 20.8%. The patients who responded to mDCF had lower plasma OPN levels than the non-responding
ones (110.7±29.3 ng/mL, 211.9±24.4 ng/mL respectively, p=0.002). The performance status
and the plasma OPN levels were found to be significant factors for overall survival in the multivariate
analysis (p=0.004 and 0.016, respectively).
Conclusion: The serum OPN seems to be a novel significant prognostic and predictive factor in patients
with advanced gastric cancer who were treated with DCF regimen.